Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy by Hweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, Bin Wu, Christian Brandl, Christian Webhofer, Mason McComb, Sabine Wittemer-Rump, Gökben Koca, Sabine Stienen, Ralf C. Bargou, Horst-Dieter Hummel, Wolfgang Loidl, Carsten Grüllich, Tobias Eggert, Ben Tran, Daniel T. Mytych

Get full text